Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Clinical evidence

Target-HTN

72 evidence topics · 8 sources

Objective
Location and study date
Registered locations and study dates
FieldQuoted record
Study start (actual)“2021-07-01”
Primary completion (actual)“2022-09-07”
Study completion (actual)“2022-10-07”
Other study ID number“MLS-101-201”
Sponsor“Mineralys Therapeutics Inc.”
Study design
Registered design details
FieldQuoted record
Phase“Phase 2”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Quadruple”
Primary purpose“Treatment”
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in office systolic blood pressure as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
FieldQuoted record
Enrollment (actual)“200”
Participants randomized and analyzed for the primary endpoint by group
GroupRandomized (baseline table)Primary end point analysis (efficacy table)
Cohort 1, lorundrostat 100 mg once daily“100 mg once daily (n = 30)”View highlighted excerpt for this quote“100 mg once daily (n = 25)”View highlighted excerpt for this quote
Cohort 1, lorundrostat 50 mg once daily“50 mg once daily (n = 28)”View highlighted excerpt for this quote“50 mg once daily (n = 28)”View highlighted excerpt for this quote
Cohort 1, lorundrostat 25 mg twice daily“25 mg twice daily (n = 30)”View highlighted excerpt for this quote“25 mg twice daily (n = 28)”View highlighted excerpt for this quote
Cohort 1, lorundrostat 12.5 mg twice daily“12.5 mg twice daily (n = 22)”View highlighted excerpt for this quote“12.5 mg twice daily (n = 19)”View highlighted excerpt for this quote
Cohort 1, lorundrostat 12.5 mg once daily“12.5 mg once daily (n = 23)”View highlighted excerpt for this quote“12.5 mg once daily (n = 19)”View highlighted excerpt for this quote
Cohort 1, placebo“Placebo (n = 30)”View highlighted excerpt for this quote“Placebo (n = 29)”View highlighted excerpt for this quote
Cohort 2, lorundrostat 100 mg once daily“Lorundrostat, 100 mg once daily (n = 31)”View highlighted excerpt for this quote“Lorundrostat, 100 mg once daily (n = 31)”View highlighted excerpt for this quote
Cohort 2, placebo“Placebo (n = 6)”View highlighted excerpt for this quote“Placebo (n = 6)”View highlighted excerpt for this quote
Description of analysis sets
Results
Participant disposition
Registered participant flow by group
DispositionPlacebo, Part 112.5 mg BID, Part 125 mg BID, Part 112.5 mg QD, Part 150 mg QD, Part 1100 mg QD, Part 1Placebo, Part 2100 mg QD, Part 2
Started“30”“22”“30”“23”“28”“30”“6”“31”
Completed“29”“18”“28”“18”“26”“27”“6”“30”
Not completed“1”“4”“2”“5”“2”“3”“0”“1”
Adverse event“0”“0”“0”“1”“0”“0”“0”“0”
Lost to follow-up“0”“1”“1”“2”“0”“1”“0”“0”
Not specified by investigator“0”“3”“0”“0”“1”“0”“0”“0”
Protocol violation“1”“0”“1”“1”“0”“1”“0”“0”
Withdrawal by subject“0”“0”“0”“1”“1”“1”“0”“1”
Baseline characteristics
Baseline characteristics by group
CharacteristicCohort 1, 100 mg QD (n = 30)Cohort 1, 50 mg QD (n = 28)Cohort 1, 25 mg BID (n = 30)Cohort 1, 12.5 mg BID (n = 22)Cohort 1, 12.5 mg QD (n = 23)Cohort 1, placebo (n = 30)Cohort 2, 100 mg QD (n = 31)Cohort 2, placebo (n = 6)
Age, mean (SD), y“68.7 (8.9)”View highlighted excerpt for this quote“64.7 (9.5)”View highlighted excerpt for this quote“64.8 (9.7)”View highlighted excerpt for this quote“68.1 (10.1)”View highlighted excerpt for this quote“65.2 (11.3)”View highlighted excerpt for this quote“62.6 (10.7)”View highlighted excerpt for this quote“66.6 (10.6)”View highlighted excerpt for this quote“62.7 (12.3)”View highlighted excerpt for this quote
Female, No. (%)“18 (60.0)”View highlighted excerpt for this quote“15 (53.6)”View highlighted excerpt for this quote“19 (63.3)”View highlighted excerpt for this quote“14 (63.6)”View highlighted excerpt for this quote“12 (52.2)”View highlighted excerpt for this quote“17 (56.7)”View highlighted excerpt for this quote“21 (67.7)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote
Black or African American, No. (%)“15 (50.0)”View highlighted excerpt for this quote“8 (28.6)”View highlighted excerpt for this quote“7 (23.3)”View highlighted excerpt for this quote“7 (31.8)”View highlighted excerpt for this quote“11 (47.8)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“6 (19.4)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote
White, No. (%)“14 (46.7)”View highlighted excerpt for this quote“19 (67.9)”View highlighted excerpt for this quote“23 (76.7)”View highlighted excerpt for this quote“15 (68.2)”View highlighted excerpt for this quote“11 (47.8)”View highlighted excerpt for this quote“13 (43.3)”View highlighted excerpt for this quote“25 (80.6)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote
Hispanic or Latino ethnicity, No. (%)“16 (53.3)”View highlighted excerpt for this quote“14 (50.0)”View highlighted excerpt for this quote“17 (56.7)”View highlighted excerpt for this quote“7 (31.8)”View highlighted excerpt for this quote“10 (43.5)”View highlighted excerpt for this quote“12 (40.0)”View highlighted excerpt for this quote“17 (54.8)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote
Body mass index, mean (SD)“30.4 (5.5)”View highlighted excerpt for this quote“32.0 (5.0)”View highlighted excerpt for this quote“30.6 (5.5)”View highlighted excerpt for this quote“32.0 (5.2)”View highlighted excerpt for this quote“30.6 (4.9)”View highlighted excerpt for this quote“31.9 (5.0)”View highlighted excerpt for this quote“30.5 (4.4)”View highlighted excerpt for this quote“32.0 (3.9)”View highlighted excerpt for this quote
Systolic AOBP at randomization, mean (SD), mm Hg“142.2 (13.4)”View highlighted excerpt for this quote“140.0 (12.1)”View highlighted excerpt for this quote“142.8 (13.1)”View highlighted excerpt for this quote“142.6 (13.3)”View highlighted excerpt for this quote“142.9 (13.7)”View highlighted excerpt for this quote“142.9 (10.7)”View highlighted excerpt for this quote“139.8 (9.1)”View highlighted excerpt for this quote“135.3 (5.5)”View highlighted excerpt for this quote
Diastolic AOBP at randomization, mean (SD), mm Hg“78.5 (10.0)”View highlighted excerpt for this quote“84.7 (7.0)”View highlighted excerpt for this quote“80.1 (9.3)”View highlighted excerpt for this quote“81.6 (9.4)”View highlighted excerpt for this quote“80.3 (12.0)”View highlighted excerpt for this quote“83.8 (9.5)”View highlighted excerpt for this quote“78.6 (10.0)”View highlighted excerpt for this quote“81.5 (7.9)”View highlighted excerpt for this quote
eGFR, mean (SD), mL/min/1.73 m2“77.4 (14.0)”View highlighted excerpt for this quote“77.2 (14.1)”View highlighted excerpt for this quote“80.9 (12.4)”View highlighted excerpt for this quote“81.7 (16.3)”View highlighted excerpt for this quote“77.9 (18.7)”View highlighted excerpt for this quote“81.6 (17.3)”View highlighted excerpt for this quote“79.9 (13.1)”View highlighted excerpt for this quote“83.9 (18.6)”View highlighted excerpt for this quote
Diabetes, No. (%)“8 (26.7)”View highlighted excerpt for this quote“8 (28.6)”View highlighted excerpt for this quote“11 (36.7)”View highlighted excerpt for this quote“9 (40.9)”View highlighted excerpt for this quote“11 (47.8)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“16 (51.6)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote
Heart failure, No. (%)“1 (3.3)”View highlighted excerpt for this quote“1 (3.6)”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“1 (4.5)”View highlighted excerpt for this quote“1 (4.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
2 background BP medications, No. (%)“14 (46.7)”View highlighted excerpt for this quote“20 (71.4)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“7 (31.8)”View highlighted excerpt for this quote“14 (60.9)”View highlighted excerpt for this quote“17 (56.7)”View highlighted excerpt for this quote“20 (64.5)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote
3 or more background BP medications, No. (%)“16 (53.3)”View highlighted excerpt for this quote“8 (28.6)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“15 (68.2)”View highlighted excerpt for this quote“9 (39.1)”View highlighted excerpt for this quote“13 (43.3)”View highlighted excerpt for this quote“11 (35.5)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote
Thiazide-type diuretic use, No. (%)“17 (56.7)”View highlighted excerpt for this quote“16 (57.1)”View highlighted excerpt for this quote“18 (60.0)”View highlighted excerpt for this quote“13 (59.1)”View highlighted excerpt for this quote“12 (52.2)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“19 (61.3)”View highlighted excerpt for this quote“5 (83.3)”View highlighted excerpt for this quote
ACE inhibitor or ARB use, No. (%)“23 (76.7)”View highlighted excerpt for this quote“20 (71.4)”View highlighted excerpt for this quote“27 (90.0)”View highlighted excerpt for this quote“17 (77.3)”View highlighted excerpt for this quote“18 (78.3)”View highlighted excerpt for this quote“22 (73.3)”View highlighted excerpt for this quote“30 (96.8)”View highlighted excerpt for this quote“5 (83.3)”View highlighted excerpt for this quote
Registered age distribution and region of enrollment
CharacteristicTotal (200 participants)
Age younger than 65 years“83”
Age 65 to 79 years“104”
Age 80 years or older“13”
Enrolled in the United States“200”
Body mass index, mean (SD), kg/m^2“31.1(5.0)”
Seated automated office systolic blood pressure, mean (SD), mmHg“141.6(12.0)”
Efficacy results
Primary end point: automated office systolic blood pressure at week 8
MeasureCohort 1, 100 mg QD (n = 25)Cohort 1, 50 mg QD (n = 28)Cohort 1, 25 mg BID (n = 28)Cohort 1, 12.5 mg BID (n = 19)Cohort 1, 12.5 mg QD (n = 19)Cohort 1, placebo (n = 29)Cohort 2, 100 mg QD (n = 31)Cohort 2, placebo (n = 6)
Baseline SBP, mean (SD), mm Hg“143.8 (12.0)”View highlighted excerpt for this quote“141.8 (10.9)”View highlighted excerpt for this quote“140.9 (9.6)”View highlighted excerpt for this quote“144.6 (10.5)”View highlighted excerpt for this quote“147.1 (11.6)”View highlighted excerpt for this quote“142.7 (10.2)”View highlighted excerpt for this quote“140.4 (8.6)”View highlighted excerpt for this quote“132.9 (8.4)”View highlighted excerpt for this quote
Week 8 SBP, mean (SD), mm Hg“131.3 (14.1)”View highlighted excerpt for this quote“128.6 (13.7)”View highlighted excerpt for this quote“131.3 (16.6)”View highlighted excerpt for this quote“131.9 (12.9)”View highlighted excerpt for this quote“140.8 (22.0)”View highlighted excerpt for this quote“139.1 (14.2)”View highlighted excerpt for this quote“129.3 (15.4)”View highlighted excerpt for this quote“128.3 (18.9)”View highlighted excerpt for this quote
Change in SBP, least-squares mean (SE), mm Hg“−11.9 (2.8)”View highlighted excerpt for this quote“−13.7 (2.7)”View highlighted excerpt for this quote“−11.1 (2.7)”View highlighted excerpt for this quote“−11.3 (3.2)”View highlighted excerpt for this quote“−5.6 (3.2)”View highlighted excerpt for this quote“−4.1 (2.6)”View highlighted excerpt for this quote“−11.4 (2.5)”View highlighted excerpt for this quoteNot reported
Difference from placebo, least-squares mean (90% CI), mm Hg“−7.8 (−14.1 to −1.5)”View highlighted excerpt for this quote“−9.6 (−15.8 to −3.4)”View highlighted excerpt for this quote“−7.0 (−13.1 to −0.8)”View highlighted excerpt for this quote“−7.2 (−14.0 to −0.4)”View highlighted excerpt for this quote“−1.5 (−8.3 to 5.3)”View highlighted excerpt for this quoteNot applicableNot reportedNot applicable
P value“.04”View highlighted excerpt for this quote“.01”View highlighted excerpt for this quote“.06”View highlighted excerpt for this quote“.08”View highlighted excerpt for this quote“.71”View highlighted excerpt for this quoteNot applicableNot reportedNot applicable
Secondary end point: automated office diastolic blood pressure at week 8
MeasureCohort 1, 100 mg QD (n = 25)Cohort 1, 50 mg QD (n = 28)Cohort 1, 25 mg BID (n = 28)Cohort 1, 12.5 mg BID (n = 19)Cohort 1, 12.5 mg QD (n = 19)Cohort 1, placebo (n = 29)Cohort 2, 100 mg QD (n = 31)Cohort 2, placebo (n = 6)
Baseline DBP, mean (SD), mm Hg“78.9 (9.6)”View highlighted excerpt for this quote“84.9 (6.4)”View highlighted excerpt for this quote“78.9 (8.0)”View highlighted excerpt for this quote“81.6 (7.6)”View highlighted excerpt for this quote“82.4 (10.7)”View highlighted excerpt for this quote“83.4 (8.8)”View highlighted excerpt for this quote“78.1 (7.6)”View highlighted excerpt for this quote“78.3 (7.6)”View highlighted excerpt for this quote
Week 8 DBP, mean (SD), mm Hg“73.0 (9.4)”View highlighted excerpt for this quote“76.8 (9.8)”View highlighted excerpt for this quote“75.4 (13.1)”View highlighted excerpt for this quote“75.2 (10.1)”View highlighted excerpt for this quote“81.4 (17.2)”View highlighted excerpt for this quote“81.3 (9.4)”View highlighted excerpt for this quote“72.2 (8.4)”View highlighted excerpt for this quote“76.2 (11.0)”View highlighted excerpt for this quote
Change in DBP, least-squares mean (SE), mm Hg“−5.8 (1.8)”View highlighted excerpt for this quote“−7.1 (1.7)”View highlighted excerpt for this quote“−4.1 (1.7)”View highlighted excerpt for this quote“−5.5 (2.0)”View highlighted excerpt for this quote“−3.8 (2.0)”View highlighted excerpt for this quote“−1.6 (1.7)”View highlighted excerpt for this quote“−5.6 (1.4)”View highlighted excerpt for this quoteNot reported
Difference from placebo, least-squares mean (90% CI), mm Hg“−4.1 (−8.1 to −0.1)”View highlighted excerpt for this quote“−5.5 (−9.4 to −1.5)”View highlighted excerpt for this quote“−2.5 (−6.4 to 1.4)”View highlighted excerpt for this quote“−3.8 (−8.2 to 0.5)”View highlighted excerpt for this quote“−2.1 (−6.5 to 2.2)”View highlighted excerpt for this quoteNot applicableNot reportedNot applicable
P value“.09”View highlighted excerpt for this quote“.02”View highlighted excerpt for this quote“.30”View highlighted excerpt for this quote“.14”View highlighted excerpt for this quote“.42”View highlighted excerpt for this quoteNot applicableNot reportedNot applicable
Secondary end point: ambulatory 24-hour blood pressure
MeasurePlacebo, Part 112.5 mg BID, Part 125 mg BID, Part 112.5 mg QD, Part 150 mg QD, Part 1100 mg QD, Part 1Placebo, Part 2100 mg QD, Part 2
Participants analyzed“26”“16”“26”“15”“28”“24”“0”“27”
Change in 24-hour mean SBP, least squares mean (SE), mmHg“-1.01(2.38)”“-5.78(3.03)”“-9.05(2.38)”“-2.51(3.15)”“-4.86(2.34)”“-6.34(2.5)”Not reported“-1.02(2.64)”
Change in 24-hour mean DBP, least squares mean (SE), mmHg“-0.90(1.46)”“-5.14(1.85)”“-6.03(1.45)”“-2.34(1.91)”“-3.64(1.40)”“-6.14(1.51)”Not reported“-0.07(1.69)”
Secondary end point: blood pressure below 130/80 mm Hg at week 8
MeasurePlacebo, Part 112.5 mg BID, Part 125 mg BID, Part 112.5 mg QD, Part 150 mg QD, Part 1100 mg QD, Part 1Placebo, Part 2100 mg QD, Part 2
Participants analyzed“30”“22”“30”“23”“28”“30”“6”“31”
Participants with blood pressure ≤ 130/80 mmHg at week 8“7”“7”“13”“6”“12”“9”“3”“17”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events and serum potassium changes by group
MeasureCohort 1, 100 mg QD (n = 30)Cohort 1, 50 mg QD (n = 28)Cohort 1, 25 mg BID (n = 30)Cohort 1, 12.5 mg BID (n = 22)Cohort 1, 12.5 mg QD (n = 23)Cohort 1, placebo (n = 30)Cohort 2, 100 mg QD (n = 31)Cohort 2, placebo (n = 6)
Any serious adverse event, No. (%)“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (9)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Any adverse event, No. (%)“17 (57)”View highlighted excerpt for this quote“12 (43)”View highlighted excerpt for this quote“20 (67)”View highlighted excerpt for this quote“13 (59)”View highlighted excerpt for this quote“16 (70)”View highlighted excerpt for this quote“12 (40)”View highlighted excerpt for this quote“19 (61)”View highlighted excerpt for this quote“1 (17)”View highlighted excerpt for this quote
Hypotension, No. (%)“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Change from baseline in serum potassium, mean (SD), mmol/L“0.29 (0.59)”View highlighted excerpt for this quote“0.25 (0.36)”View highlighted excerpt for this quote“0.34 (0.46)”View highlighted excerpt for this quote“0.32 (0.53)”View highlighted excerpt for this quote“0.31 (0.44)”View highlighted excerpt for this quote“0.03 (0.37)”View highlighted excerpt for this quote“0.21 (0.54)”View highlighted excerpt for this quote“−0.05 (0.28)”View highlighted excerpt for this quote
Serum potassium 5.6-6.0 mmol/L, No. (%)“5 (16)”View highlighted excerpt for this quote“1 (4)”View highlighted excerpt for this quote“2 (7)”View highlighted excerpt for this quote“2 (9)”View highlighted excerpt for this quote“3 (13)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Serum potassium 6.1-6.5 mmol/L, No. (%)“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“1 (5)”View highlighted excerpt for this quote“1 (4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Serum potassium >6.5 mmol/L, No. (%)“1 (3)”View highlighted excerpt for this quote“1 (4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Registered serious and other adverse events by group
Adverse event, affected / at risk (%)Placebo, Part 112.5 mg BID, Part 125 mg BID, Part 112.5 mg QD, Part 150 mg QD, Part 1100 mg QD, Part 1Placebo, Part 2100 mg QD, Part 2
All-cause mortality“0/30 (0.00%)”“0/22 (0.00%)”“0/30 (0.00%)”“0/23 (0.00%)”“0/28 (0.00%)”“0/30 (0.00%)”“0/6 (0.00%)”“0/31 (0.00%)”
Serious adverse events, total“0/30 (0.00%)”“0/22 (0.00%)”“0/30 (0.00%)”“2/23 (8.70%)”“0/28 (0.00%)”“0/30 (0.00%)”“0/6 (0.00%)”“1/31 (3.23%)”
Other adverse events, total“7/30 (23.33%)”“13/22 (59.09%)”“18/30 (60.00%)”“16/23 (69.57%)”“10/28 (35.71%)”“16/30 (53.33%)”“1/6 (16.67%)”“19/31 (61.29%)”
Hyperkalemia“1/30 (3.33%)”“5/22 (22.73%)”“9/30 (30.00%)”“6/23 (26.09%)”“3/28 (10.71%)”“8/30 (26.67%)”“0/6 (0.00%)”“8/31 (25.81%)”
Glomerular filtration rate decreased“1/30 (3.33%)”“3/22 (13.64%)”“0/30 (0.00%)”“1/23 (4.35%)”“0/28 (0.00%)”“5/30 (16.67%)”“0/6 (0.00%)”“1/31 (3.23%)”
Blood creatinine increased“0/30 (0.00%)”“0/22 (0.00%)”“0/30 (0.00%)”“0/23 (0.00%)”“0/28 (0.00%)”“3/30 (10.00%)”“0/6 (0.00%)”“1/31 (3.23%)”
Urinary tract infection“0/30 (0.00%)”“0/22 (0.00%)”“3/30 (10.00%)”“1/23 (4.35%)”“2/28 (7.14%)”“1/30 (3.33%)”“0/6 (0.00%)”“2/31 (6.45%)”
Hypotension“0/30 (0.00%)”“1/22 (4.55%)”“0/30 (0.00%)”“0/23 (0.00%)”“0/28 (0.00%)”“1/30 (3.33%)”“0/6 (0.00%)”“1/31 (3.23%)”
Orthostatic hypotension“0/30 (0.00%)”“1/22 (4.55%)”“0/30 (0.00%)”“2/23 (8.70%)”“0/28 (0.00%)”“0/30 (0.00%)”“0/6 (0.00%)”“0/31 (0.00%)”
Hypertension“0/30 (0.00%)”“0/22 (0.00%)”“1/30 (3.33%)”“2/23 (8.70%)”“2/28 (7.14%)”“0/30 (0.00%)”“0/6 (0.00%)”“0/31 (0.00%)”
Cortisol decreased“1/30 (3.33%)”“2/22 (9.09%)”“1/30 (3.33%)”“0/23 (0.00%)”“0/28 (0.00%)”“0/30 (0.00%)”“0/6 (0.00%)”“0/31 (0.00%)”
Study limitations
Summary

Target-HTN was a phase 2, dose-ranging trial that randomized 200 participants at sites in the United States to five lorundrostat regimens or placebo for 8 weeks, with no adjustment for multiplicity and with treatment differences reported as 90% confidence intervals. In cohort 1, the primary analysis included 19 to 29 participants per group, and the authors state that “each studied dose had a limited sample size”. Randomization to the 12.5 mg once-daily and 12.5 mg twice-daily groups stopped after the January 2022 interim analysis, and two interim analyses were performed in total. Cohort 1 enrolled only participants with suppressed renin; cohort 2 (37 participants, 6 receiving placebo) was exploratory, with no formal statistical testing against placebo. Sustained hypertension was not confirmed by 24-hour ambulatory monitoring before randomization, which the authors associate with “a prominent white-coat effect” in the 50 mg once-daily group. Participants with an eGFR below 60 mL/min/1.73 m2, or with serum potassium above 5.2 mmol/L (cohort 1) or 4.8 mmol/L (cohort 2), were excluded. The registered results define the proportion at goal as blood pressure of 130/80 mmHg or lower at week 8, while the publication describes it as below 130/80 mm Hg at week 7 or 8. The trial protocol was designed by the sponsor, Mineralys Therapeutics, which also provided input on the manuscript.